Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabilized by Lumigan® 0.01 % or Xalatan® with ocular surface intolerance. Phase IV, international, multicentre, randomised, investigator masked, 3 months duration, 3 parallel groups, 3 X 120 evaluable patients

Trial Profile

Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabilized by Lumigan® 0.01 % or Xalatan® with ocular surface intolerance. Phase IV, international, multicentre, randomised, investigator masked, 3 months duration, 3 parallel groups, 3 X 120 evaluable patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Latanoprost (Primary) ; Bimatoprost
  • Indications Glaucoma; Ocular hypertension
  • Focus Adverse reactions
  • Sponsors Laboratoires Thea
  • Most Recent Events

    • 27 Jul 2017 This trial has been completed in Greece (end date: 28 Jul 2017).
    • 18 Mar 2017 This trial has been completed in the United Kingdom (end date: 28 Jul 2016).
    • 28 Oct 2016 This trial was completed in Spain, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top